



Notice of Results

8 March 2017

London, 8 March 2017 - Silence Therapeutics plc, AIM:SLN ("Silence" or "the Company") a leader in the discovery, delivery and development of novel RNA therapeutics for the treatment of serious diseases with unmet medical need, plans to announce its Preliminary Results for the year ended 31 December 2016 on Tuesday 28 March 2017.

Enquiries:

Silence Therapeutics plc Ali Mortazavi, Chief Executive Officer David Ellam, Chief Financial Officer	Tel: +44 (0)20 3457 6900
Canaccord Genuity Limited (Nominated Adviser and Joint Broker) Henry Fitzgerald-O'Connor/Emma Gabriel	Tel: +44 (0)20 7523 8350
Peel Hunt LLP (Joint Broker) James Steel/Oliver Jackson	Tel: +44 (0)20 7418 8900
Media Enquiries: FTI Consulting Simon Conway/Brett Pollard/Stephanie Cuthbert	Tel: +44 (0) 20 3727 1000

Notes to Editors

About Silence Therapeutics plc

Silence Therapeutics develops a new generation of medicines by harnessing the body's natural mechanism of RNA interference, or RNAi, within its cells. Our proprietary technology can selectively inhibit any gene in the genome, specifically silencing the production of disease-causing proteins. Using our enabling delivery systems, we have achieved an additional level of specificity by delivering our therapeutic RNA molecules exclusively to target cells. Silence's proprietary RNA chemistries and delivery systems are designed to improve the stability of our molecules and enhance effective delivery to target cells, providing a powerful modular technology well suited to tackle life-threatening diseases.